Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.50 per share a year ago. These figures are ...

KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s ...

Kymera Therapeutics, Inc. has outlined its key objectives for 2025, emphasizing its strategy to advance a portfolio of oral immunology programs. The company is currently making progress with several ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

Anitra AZTR stock moved upwards by 89.1% to $0.53 during Tuesday's pre-market session. The company's market cap stands at $6.5 million. Evaxion Biotech EVAX stock increas ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and Oppenheimer 35 th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m ...

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and ...

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...

Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases ...